Chemovaccination Shows Promise Against Malaria

Malaria is a significant global health problem, responsible for an estimated 600,000 deaths each year. To combat this issue, researchers have explored various approaches, including vaccine development and new treatments.

A collaboration between Merck and the Walter and Eliza Hall Institute of Medical Research (WEHI) aimed to find a novel antimalarial approach by targeting malaria proteins called plasmepsins. These enzymes are crucial for the parasite's survival and are conserved across different malaria species, making them an attractive target.

The researchers developed a dual inhibitor of plasmepsin IX and X, called WM382, which effectively cleared mouse models of malaria in preclinical studies. However, this compound needed optimization to be suitable for human use, leading to the development of MK-7602. In clinical trials, both drugs demonstrated promising results.

The study's authors wanted to investigate whether these compounds could induce an immune response that would protect against future infections. By administering WM382 or MK-7602 to mice infected with malaria, they found that the treatment resulted in defective and noninfectious liver-derived merozoites. These 'chemo-attenuated liver merozoites' (CALM) elicited a robust immune response, providing long-lasting protection against malaria.

The results suggest that chemovaccination, which combines chemotherapy with immunization, could be an effective approach for both treating and preventing malaria. This method has the potential to offer long-term immunity against the disease, reducing the need for repeated treatments and vaccinations.